This clinical trial study aims to compare the effectiveness and safety of secretome from ADSCs with minoxidil in AGA cases, to provide future reference or standard in the application of cell-based therapy and its derivatives in AGA cases. The subject of this study is androgenetic alopecia population. The main questions it aims to answer are: * Is the secretome of ADSC's effective compared to minoxidil? * Is the secretome of ADSC's safe compared to minoxidil? * Is the combination of the secretome of ADSC's and minoxidil better in safety and effectiveness compared to secretome or minoxidil alone?
This study was a single-blind clinical trial using an experimental research design on subjects with androgenetic alopecia. Variables tested in this study were the method of "treatment of AGA by administering secretome concentrate alone, compared to using minoxidil alone and with a combination of both." Subjects were divided into 3 groups: * 20 subjects received secretome * 20 subjects received minoxidil * 20 subjects received both treatments Participants will undergo history taking, and a physical examination (including vital signs, body weight, and hair pull test). Pictures of patients' head were then taken and the hair loss degree was graded using Hamilton-Norwood. Hair growth was evaluated every month starting from months 0, 1, 2, and 3. Clinical assessment of hair growth was examined through physical and supporting examinations including photography, trichoscan, and trichoscopy. The sample size for this study was calculated with the help of G\*Power version 3.1 software (Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany). The inclusion and exclusion criteria are applied. Statistical data were analyzed using SPSS® version 21 software. On numerical data, normality analysis was carried out using the Kolmogorov-Smirnov test.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
20 subjects received minoxidil only for the treatment of AGA
20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA
20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA
RSUP Nasional Cipto Mangunkusumo
Jakarta Pusat, DKI Jakarta, Indonesia
Universitas Indonesia
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Improvement of alopecia in physical examination
The investigator conduct a scalp examination every 4 weeks until the twelfth week to measure the improvement of alopecia with Hamilton-Norwood scale
Time frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
Macroscopic hair growth documented
The investigator conducted documentation of the subject in 7 positions, so that the improvement of alopecia can be seen from various directions
Time frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
Microscopic hair growth evaluated by Trichoscopy
Microscopic hair growth was documented using Heine® Delta 20 Plus (Heine, Germany) dermoscopy for qualitative measurement
Time frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
Microscopic hair growth evaluated by Trichoscan
The investigator use Fotofinder® medicam 1000 s video-trichoscopy (FotoFinder Systems GmbH, Germany) for quantitative measurements, such as hair rate anagen (%), hair rate telogen (%), hair rate terminal (%), and hair rate vellus (%)
Time frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
Patient satisfaction
The patient satisfaction scale using a linear analog scale with a scale of 1-7 (1 = no result, 7 = very satisfactory outcome) and was evaluated at the last treatment session.
Time frame: Week 12 (end of trial)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
60